Innate Pharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 11.5, which predicts an increase of 502.09% from the current stock price of 1.91.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11.5	$11.5	$11.5	$11.5
Change	+502.09%	+502.09%	+502.09%	+502.09%

Analyst Ratings

According to 1 stock analyst, the rating for Innate Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+502.09%	Mar 28, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+502.09%	Feb 6, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+502.09%	Jan 17, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+502.09%	Dec 9, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+502.09%	Nov 15, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

64.48M

from 20.12M

220.44%

from 20.12M

Revenue Next Year

117.25M

from 64.48M

81.85%

from 64.48M

EPS This Year

0.06

from -0.61

EPS Next Year

0.85

from 0.06

1,226.39%

from 0.06

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	69.77M	24.70M	57.67M	61.64M	20.12M	64.48M	117.25M	105.53M
Revenue Growth	-18.35%	-64.60%	133.47%	6.88%	-67.36%	220.44%	81.85%	-10.00%
EPS	-0.81	-0.66	-0.73	-0.09	-0.61	0.06	0.85	-
EPS Growth	-	-	-	-	-	-	1,226.39%	-
Forward PE	-	-	-	-	-	27.62	2.08	-
No. Analysts	-	-	-	-	-	6	6	3

Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	193.2M	302.4M	148.8M
Avg	64.5M	117.3M	105.5M
Low	6.9M	19.1M	65.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	860.2%	369.0%	26.9%
Avg	220.4%	81.9%	-10.0%
Low	-65.9%	-70.4%	-43.8%

EPS Forecast

EPS	2025	2026
High	1.41	1.88
Avg	0.06	0.85
Low	-0.67	-0.19

EPS Growth

EPS Growth	2025	2026
High	-	2,838.4%
Avg	-	1,226.4%
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.